Search

Your search keyword '"Alakel, Nael"' showing total 246 results
Start Over Author "Alakel, Nael"
246 results on '"Alakel, Nael"'

2. Molecular subgroups of T-cell acute lymphoblastic leukemia in adults treated according to pediatric-based GMALL protocols

Author

Neumann, Martin, Beder, Thomas, Bastian, Lorenz, Hänzelmann, Sonja, Bultmann, Miriam, Wolgast, Nadine, Hartmann, Alina, Trautmann, Heiko, Ortiz-Tanchez, Jutta, Schlee, Cornelia, Schroeder, Michael, Fransecky, Lars, Vosberg, Sebastian, Fiedler, Walter, Alakel, Nael, Heberling, Lisa, Kondakci, Mustafa, Starck, Michael, Schwartz, Stefan, Raffel, Simon, Müller-Tidow, Carsten, Schneller, Folker, Reichle, Albrecht, Burmeister, Thomas, Greif, Philipp A., Brüggemann, Monika, Gökbuget, Nicola, and Baldus, Claudia D.

Published
2024
Full Text
View/download PDF

3. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

Author

Alakel, Nael, Albring, Jörn, Berdel, Wolfgang E., Bethge, Wolfgang, Bornhäuser, Martin, Bug, Gesine, Buhl, Christoph, Call, Simon, Crysandt, Martina, Egger-Heidrich, Katharina, Eßeling, Eva, Faul, Christoph, Franke, Georg-Nikolaus, Georgi, Julia-Annabell, Glück-Wolf, Julia, Groth, Christoph, Hauptrock, Beate, Heidenreich, Daniela, Janjetovic, Snjezana, Jost, Edgar, Kaufmann, Martin, Kindler, Thomas, Klein, Stefan A., Krause, Stefan W., Kreil, Sebastian, Kretschmann, Theresa, Kunadt, Desiree, Lang, Fabian, Lenz, Georg, Martin, Sonja, Marx, Julia, Middeke, Jan-Moritz, Mikesch, Jan-Henrik, Müller, Lutz P., Müller, Nadine, Niederland, Judith, Parmentier, Stefani, Petzold, Kathrin, Platzbecker, Uwe, Rank, Andreas, Reicherts, Christian, Röllig, Christoph, Rösler, Wolf, Schäfer-Eckart, Kerstin, Schaffrath, Judith, Schaich, Markus, Schetelig, Johannes, Schliemann, Christoph, Schmid, Christoph, Schneidawind, Dominik, Schubert, Jörg, Serve, Hubert, Sockel, Katja, Steffen, Björn, Stelljes, Matthias, Teipel, Raphael, von Bonin, Malte, Wagner-Drouet, Eva, Wass, Maxi, Wendelin, Knut, Middeke, Jan Moritz, Wagner-Drouet, Eva-Maria, Müller, Lutz P, Krause, Stefan W, Klein, Stefan A, Baldauf, Henning, Stölzel, Friedrich, Petzold, Cathleen, Kriege, Oliver, Berdel, Wolfgang E, Ehninger, Gerhard, and Schmidt, Alexander H

Published
2024
Full Text
View/download PDF

4. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial

Author

Denkinger, Claudia M., Janssen, Maike, Schäkel, Ulrike, Gall, Julia, Leo, Albrecht, Stelmach, Patrick, Weber, Stefan F., Krisam, Johannes, Baumann, Lukas, Stermann, Jacek, Merle, Uta, Weigand, Markus A., Nusshag, Christian, Bullinger, Lars, Schrezenmeier, Jens-Florian, Bornhäuser, Martin, Alakel, Nael, Witzke, Oliver, Wolf, Timo, Vehreschild, Maria J. G. T., Schmiedel, Stefan, Addo, Marylyn M., Herth, Felix, Kreuter, Michael, Tepasse, Phil-Robin, Hertenstein, Bernd, Hänel, Mathias, Morgner, Anke, Kiehl, Michael, Hopfer, Olaf, Wattad, Mohammad-Amen, Schimanski, Carl C., Celik, Cihan, Pohle, Thorsten, Ruhe, Matthias, Kern, Winfried V., Schmitt, Anita, Lorenz, Hanns-Martin, Souto-Carneiro, Margarida, Gaeddert, Mary, Halama, Niels, Meuer, Stefan, Kräusslich, Hans-Georg, Müller, Barbara, Schnitzler, Paul, Parthé, Sylvia, Bartenschlager, Ralf, Gronkowski, Martina, Klemmer, Jennifer, Schmitt, Michael, Dreger, Peter, Kriegsmann, Katharina, Schlenk, Richard F., and Müller-Tidow, Carsten

Published
2023
Full Text
View/download PDF

5. Long-Term Results of Allogeneic Stem Cell Transplantation in Adult Ph- Negative High-Risk Acute Lymphoblastic Leukemia

Author

Beelen, Dietrich W., Arnold, Renate, Stelljes, Matthias, Alakel, Nael, Brecht, Arne, Bug, Gesine, Bunjes, Donald, Faul, Christoph, Finke, Jürgen, Franke, Georg-Nikolaus, Holler, Ernst, Kobbe, Guido, Kröger, Nicolaus, Rösler, Wolf, Scheid, Christof, Schönland, Stefan, Stadler, Michael, Tischer, Johanna, Wagner-Drouet, Eva, Wendelin, Knut, Brüggemann, Monika, Reiser, Lena, Hoelzer, Dieter, and Gökbuget, Nicola

Published
2022
Full Text
View/download PDF

6. Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia.

Author

Röllig, Christoph, Steffen, Björn, Schliemann, Christoph, Mikesch, Jan-Henrik, Alakel, Nael, Herbst, Regina, Hänel, Mathias, Noppeney, Richard, Hanoun, Maher, Kaufmann, Martin, Weinbergerova, Barbora, Schäfer-Eckart, Kerstin, Sauer, Tim, Neubauer, Andreas, Burchert, Andreas, Baldus, Claudia D., Mertová, Jolana, Jost, Edgar, Niemann, Dirk, and Novák, Jan

Published
2025
Full Text
View/download PDF

9. Predictive Factors for Outcome of First Allogeneic Transplant for Elderly Patients With Acute Lymphoblastic Leukemia

Author

Bazarbachi, Abdul Hamid, Labopin, Myriam, Kröger, Nicolaus, Brecht, Arne, Blaise, Didier, Clausen, Johannes, Fanin, Renato, Einsele, Herman, Cavanna, Luigi, Itäla-Remes, Maija, Bulabois, Claude Eric, Kündgen, Lukas, Martin, Hans, Schmid, Christof, Wagner-Drouet, Eva Maria, Alakel, Nael, Bazarbachi, Ali, Savani, Bipin, Nagler, Arnon, and Mohty, Mohamad

Published
2021
Full Text
View/download PDF

10. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematologic malignancies and solid tumors: 2020 updated guidelines of the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO/DGHO)

Author

Classen, Annika Y., Henze, Larissa, von Lilienfeld-Toal, Marie, Maschmeyer, Georg, Sandherr, Michael, Graeff, Luisa Durán, Alakel, Nael, Christopeit, Maximilian, Krause, Stefan W., Mayer, Karin, Neumann, Silke, Cornely, Oliver A., Penack, Olaf, Weißinger, Florian, Wolf, Hans-Heinrich, and Vehreschild, Jörg Janne

Published
2021
Full Text
View/download PDF

11. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial

Author

Stelljes, Matthias, Middeke, Jan Moritz, Bug, Gesine, Wagner-Drouet, Eva-Maria, Müller, Lutz P, Schmid, Christoph, Krause, Stefan W, Bethge, Wolfgang, Jost, Edgar, Platzbecker, Uwe, Klein, Stefan A, Schubert, Jörg, Niederland, Judith, Kaufmann, Martin, Schäfer-Eckart, Kerstin, Schaich, Markus, Baldauf, Henning, Stölzel, Friedrich; https://orcid.org/0000-0003-0653-5332, Petzold, Cathleen, Röllig, Christoph, Alakel, Nael, Steffen, Björn, Hauptrock, Beate, Schliemann, Christoph, Sockel, Katja, Lang, Fabian, Kriege, Oliver, Schaffrath, Judith, Reicherts, Christian, Study Alliance Leukemia and the German Cooperative Transplant, Schneidawind, Dominik; https://orcid.org/0000-0002-2672-431X, et al, Stelljes, Matthias, Middeke, Jan Moritz, Bug, Gesine, Wagner-Drouet, Eva-Maria, Müller, Lutz P, Schmid, Christoph, Krause, Stefan W, Bethge, Wolfgang, Jost, Edgar, Platzbecker, Uwe, Klein, Stefan A, Schubert, Jörg, Niederland, Judith, Kaufmann, Martin, Schäfer-Eckart, Kerstin, Schaich, Markus, Baldauf, Henning, Stölzel, Friedrich; https://orcid.org/0000-0003-0653-5332, Petzold, Cathleen, Röllig, Christoph, Alakel, Nael, Steffen, Björn, Hauptrock, Beate, Schliemann, Christoph, Sockel, Katja, Lang, Fabian, Kriege, Oliver, Schaffrath, Judith, Reicherts, Christian, Study Alliance Leukemia and the German Cooperative Transplant, Schneidawind, Dominik; https://orcid.org/0000-0002-2672-431X, and et al

Abstract

BACKGROUND Whether high-dose cytarabine-based salvage chemotherapy, administered to induce complete remission in patients with poor responsive or relapsed acute myeloid leukaemia scheduled for allogeneic haematopoietic stem-cell transplantation (HSCT) after intensive conditioning confers a survival advantage, is unclear. METHODS To test salvage chemotherapy before allogeneic HSCT, patients aged between 18 and 75 years with non-favourable-risk acute myeloid leukaemia not in complete remission after first induction or untreated first relapse were randomly assigned 1:1 to remission induction with high-dose cytarabine (3 g/m$^{2}$ intravenously, 1 g/m$^{2}$ intravenously for patients >60 years or with a substantial comorbidity) twice daily on days 1-3 plus mitoxantrone (10 mg/m$^{2}$ intravenously) on days 3-5 or immediate allogeneic HSCT for the disease control group. Block randomisation with variable block lengths was used and patients were stratified by age, acute myeloid leukaemia risk, and disease status. The study was open label. The primary endpoint was treatment success, defined as complete remission on day 56 after allogeneic HSCT, with the aim to show non-inferiority for disease control compared with remission induction with a non-inferiority-margin of 5% and one-sided type 1 error of 2·5%. The primary endpoint was analysed in both the intention-to-treat (ITT) population and in the per-protocol population. The trial is completed and was registered at ClinicalTrials.gov, NCT02461537. FINDINGS 281 patients were enrolled between Sept 17, 2015, and Jan 12, 2022. Of 140 patients randomly assigned to disease control, 135 (96%) proceeded to allogeneic HSCT, 97 (69%) after watchful waiting only. Of 141 patients randomly assigned to remission induction, 134 (95%) received salvage chemotherapy and 128 (91%) patients subsequently proceeded to allogeneic HSCT. In the ITT population, treatment success was observed in 116 (83%) of 140 patients in the disease control group v

Published
2024

12. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

Author

Rautenberg, Christina, Stölzel, Friedrich, Röllig, Christoph, Stelljes, Matthias, Gaidzik, Verena, Lauseker, Michael, Kriege, Oliver, Verbeek, Mareike, Unglaub, Julia Marie, Thol, Felicitas, Krause, Stefan W., Hänel, Mathias, Neuerburg, Charlotte, Vucinic, Vladan, Jehn, Christian-Friedrich, Severmann, Julia, Wass, Maxi, Fransecky, Lars, Chemnitz, Jens, Holtick, Udo, Schäfer-Eckart, Kerstin, Schröder, Josephine, Kraus, Sabrina, Krüger, William, Kaiser, Ulrich, Scholl, Sebastian, Koch, Kathrin, Henning, Lea, Kobbe, Guido, Haas, Rainer, Alakel, Nael, Röhnert, Maximilian-Alexander, Sockel, Katja, Hanoun, Maher, Platzbecker, Uwe, Holderried, Tobias A. W., Morgner, Anke, Heuser, Michael, Sauer, Tim, Götze, Katharina S., Wagner-Drouet, Eva, Döhner, Konstanze, Döhner, Hartmut, Schliemann, Christoph, Schetelig, Johannes, Bornhäuser, Martin, Germing, Ulrich, Schroeder, Thomas, and Middeke, Jan Moritz

Published
2021
Full Text
View/download PDF

13. Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia—Lessons Learned from the Prospective BRIDGE Trial

Author

Middeke, Jan Moritz, Herbst, Regina, Parmentier, Stefani, Bug, Gesine, Hänel, Mathias, Stuhler, Gernot, Schäfer-Eckart, Kerstin, Rösler, Wolf, Klein, Stefan, Bethge, Wolfgang, Bitz, Ulrich, Büttner, Bozena, Knoth, Holger, Alakel, Nael, Schaich, Markus, Morgner, Anke, Kramer, Michael, Sockel, Katja, von Bonin, Malte, Stölzel, Friedrich, Platzbecker, Uwe, Röllig, Christoph, Thiede, Christian, Ehninger, Gerhard, Bornhäuser, Martin, and Schetelig, Johannes

Published
2017
Full Text
View/download PDF

14. P352: PROPHYLACTIC AND PREEMPTIVE USE OF DLI COMPARE FAVOURABLY TO THEIR THERAPEUTIC USE IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) – RESULTS OF A MULTICENTRE RETROSPECTIVE STUDY

Author

Haupt, Maik, primary, Jäkel, Nadja, additional, Wachsmuth, Maria, additional, Stadler, Michael, additional, Beelen, Dietrich, additional, Finke, Juergen, additional, Alakel, Nael, additional, Hemmati, Philipp, additional, Schönland, Stefan, additional, Bethge, Wolfgang, additional, Wulf, Gerald, additional, Wolff, Daniel, additional, Maria Tischer, Johanna, additional, Wagner-Drouet, Eva, additional, Brandt, Anna, additional, Kröger, Nicolaus, additional, Vucinic, Vladan, additional, Bärmann, Ben-Niklas, additional, Brüggemann, Monika, additional, Gromann, Cora, additional, Müller-Tidow, Carsten, additional, Gökbuget, Nicola, additional, and Mueller, Lutz, additional

Published
2023
Full Text
View/download PDF

15. Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope

Author

Del Principe, Maria Ilaria, Seidel, Danila, Criscuolo, Marianna, Dargenio, Michelina, Racil, Zdenek, Piedimonte, Monica, Marchesi, Francesco, Nadali, Gianpaolo, Koehler, Philipp, Fracchiolla, Nicola, Cattaneo, Chiara, Klimko, Nikolai, Spolzino, Angelica, Karapinar, Deniz Yilmaz, Demiraslan, Hayati, Duarte, Rafael F., Demeter, Judit, Stanzani, Marta, Melillo, Lorella Maria Antonia, Basilico, Claudia Maria, Cesaro, Simone, Paterno, Giovangiacinto, Califano, Catello, Delia, Mario, Buzzatti, Elisa, Busca, Alessandro, Cornely, Oliver A., Pagano, Livio, Alakel, Nael, Arsenijevi'c, Valentina Arsi'c, Camus, Vincent, Falces-Romero, Iker, Itzhak, Levy, Kouba, Michal, Martino, Rodrigo, Sedlacek, Petr, Weinbergerova, Barbora, Del Principe, Maria Ilaria, Seidel, Danila, Criscuolo, Marianna, Dargenio, Michelina, Racil, Zdenek, Piedimonte, Monica, Marchesi, Francesco, Nadali, Gianpaolo, Koehler, Philipp, Fracchiolla, Nicola, Cattaneo, Chiara, Klimko, Nikolai, Spolzino, Angelica, Karapinar, Deniz Yilmaz, Demiraslan, Hayati, Duarte, Rafael F., Demeter, Judit, Stanzani, Marta, Melillo, Lorella Maria Antonia, Basilico, Claudia Maria, Cesaro, Simone, Paterno, Giovangiacinto, Califano, Catello, Delia, Mario, Buzzatti, Elisa, Busca, Alessandro, Cornely, Oliver A., Pagano, Livio, Alakel, Nael, Arsenijevi'c, Valentina Arsi'c, Camus, Vincent, Falces-Romero, Iker, Itzhak, Levy, Kouba, Michal, Martino, Rodrigo, Sedlacek, Petr, and Weinbergerova, Barbora

Abstract

Background Our multicentre study aims to identify baseline factors and provide guidance for therapeutic decisions regarding Magnusiomyces-associated infections, an emerging threat in patients with haematological malignancies. Methods HM patients with proven (Magnusiomyces capitatus) M. capitatus or (Magnusiomyces clavatus) M. clavatus (formerly Saprochaete capitata and Saprochaete clavata) infection diagnosed between January 2010 and December 2020 were recorded from the SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group and FungiScope (Global Emerging Fungal Infection Registry). Cases of Magnusiomyces fungemia were compared with candidemia. Results Among 90 Magnusiomyces cases (60 [66%] M. capitatus and 30 (34%) M. clavatus), median age was 50 years (range 2-78), 46 patients (51%) were female and 67 (74%) had acute leukaemia. Thirty-six (40%) of Magnusiomyces-associated infections occurred during antifungal prophylaxis, mainly with posaconazole (n = 13, 36%) and echinocandins (n = 12, 34%). Instead, the candidemia rarely occurred during prophylaxis (p < .0001). First-line antifungal therapy with azoles, alone or in combination, was associated with improved response compared to other antifungals (p = .001). Overall day-30 mortality rate was 43%. Factors associated with higher mortality rates were septic shock (HR 2.696, 95% CI 1.396-5.204, p = .003), corticosteroid treatment longer than 14 days (HR 2.245, 95% CI 1.151-4.376, p = .018) and lack of neutrophil recovery (HR 3.997, 95% CI 2.102-7.601, p < .001). The latter was independently associated with poor outcome (HR 2.495, 95% CI 1.192-5.222, p = .015). Conclusions Magnusiomyces-associated infections are often breakthrough infections. Effective treatment regimens of these infections remain to be determined, but neutrophil recovery appears to play an important role in the favourable outcome.

Published
2023

16. Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome–Negative B-Precursor ALL.

Author

Stelljes, Matthias, Raffel, Simon, Alakel, Nael, Wäsch, Ralph, Kondakci, Mustafa, Scholl, Sebastian, Rank, Andreas, Hänel, Mathias, Spriewald, Bernd, Hanoun, Maher, Martin, Sonja, Schwab, Katjana, Serve, Hubert, Reiser, Lena, Knaden, Julian, Pfeifer, Heike, Marx, Julia, Sauer, Tim, Berdel, Wolfgang E., and Lenz, Georg

Published
2024
Full Text
View/download PDF

17. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO)

Author

Mellinghoff, Sibylle C., Panse, Jens, Alakel, Nael, Behre, Gerhard, Buchheidt, Dieter, Christopeit, Maximilian, Hasenkamp, Justin, Kiehl, Michael, Koldehoff, Michael, Krause, Stefan W., Lehners, Nicola, von Lilienfeld-Toal, Marie, Löhnert, Annika Y., Maschmeyer, Georg, Teschner, Daniel, Ullmann, Andrew J., Penack, Olaf, Ruhnke, Markus, Mayer, Karin, Ostermann, Helmut, Wolf, Hans-H., and Cornely, Oliver A.

Published
2017
Full Text
View/download PDF

18. Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)

Author

Stelljes, Matthias, Alakel, Nael, Wäsch, Ralph, Scholl, Sebastian, Nachtkamp, Kathrin, Rank, Andreas, Haenel, Mathias, Spriewald, Bernd, Hanoun, Maher, Martin, Sonja, Schwab, Katjana, Knaden, Julian, Reiser, Lena, Marx, Julia, Wethmar, Klaus, Sauer, Tim, Berdel, Wolfgang E., Lenz, Georg, Brüggemann, Monika, Raffel, Simon, and Goekbuget, Nicola

Subjects
Immunology, ddc:610, Cell Biology, Hematology, Biochemistry
Published
2022
Full Text
View/download PDF

19. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients with Intermediate-Risk Acute Myeloid Leukemia : A Randomized Clinical Trial

Author

Bornhäuser, Martin, Schliemann, Christoph, Schetelig, Johannes, Röllig, Christoph, Kramer, Michael, Glass, Bertram, Platzbecker, Uwe, Burchert, Andreas, Hänel, Mathias, Müller, Lutz P., Klein, Stefan, Bug, Gesine, Beelen, Dietrich, Rösler, Wolf, Schäfer-Eckart, Kerstin, Schmid, Christoph, Jost, Edgar, Lenz, Georg, Tischer, Johanna, Spiekermann, Karsten, Pfirrmann, Markus, Serve, Hubert, Stölzel, Friedrich, Alakel, Nael, Middeke, Jan Moritz, Thiede, Christian, Ehninger, Gerhard, Berdel, Wolfgang E., and Stelljes, Matthias

Subjects
Cancer Research, Oncology, Medizin
Abstract

ImportanceThe ideal postremission strategy in intermediate-risk acute myeloid leukemia (AML) in first complete remission (CR) has been a matter of debate.ObjectiveTo explore the optimal therapy for patients with intermediate-risk AML after first complete remission.Design, Settings, and ParticipantsThis investigator-initiated, open-label, 2-armed, phase 3 randomized clinical trial assessed patients at 16 hospitals in Germany from February 2, 2011, until July 1, 2018. Key eligibility criteria included cytogenetically defined intermediate-risk AML according to Medical Research Council classification, first CR or CR with incomplete blood cell count recovery after conventional induction therapy, age of 18 to 60 years, and availability of a human leukocyte antigen (HLA)–matched sibling or unrelated donor. A detailed statistical analysis plan was written and finalized on July 7, 2020. Data were exported for analysis on April 13, 2021.InterventionsPatients were randomized 1:1 to receive allogeneic hematopoietic cell transplantation (HCT) or high-dose cytarabine for consolidation and salvage HCT only in case of relapse. Strata for randomization included age (18-40 vs 41-60 years), NPM1 and CEBPA variation status, and donor type (unrelated vs related).Main Outcomes and MeasuresEnd points included overall-survival as the primary outcome and disease-free survival, cumulative incidence of relapse, treatment-related mortality, and quality of life measured according to the Medical Outcomes Study 36-Item Short-Form Health Survey as secondary outcomes.ResultsA total of 143 patients (mean [SD] age, 48.2 [9.8] years; 81 [57%] male) with AML who fulfilled the eligibility criteria were randomized. In the intention-to-treat analysis, the probability of survival at 2 years was 74% (95% CI, 62%-83%) after primary allogeneic HCT and 84% (95% CI, 73%-92%) after consolidation chemotherapy (P = .22). Disease-free survival after HCT at 2 years was 69% (95% CI, 57%-80%) compared with 40% (95% CI, 28%-53%) after consolidation chemotherapy (P = .001). Allogeneic HCT during the first CR was associated with a cumulative incidence of relapse at 2 years of 20% (95% CI, 13%-31%) compared with 58% (95% CI, 47%-71%; P P = .005). Similar outcomes were observed when analyses were confined to the 96 patients at intermediate risk according to the European Leukemia Network classification. Most importantly, all 41 patients relapsing after consolidation chemotherapy (36 hematologic, 4 molecular, and 1 extramedullary) proceeded to allogeneic HCT. No significant differences in health-related quality of life measures were observed between groups.Conclusions and RelevancePrimary allogeneic HCT during first CR was not associated with superior overall survival compared with consolidation chemotherapy in patients 60 years or younger with intermediate-risk AML during the first CR and an available donor.Trial RegistrationClinicalTrials.gov Identifier: NCT01246752

Published
2023

20. Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia

Author

Bornhäuser, Martin, primary, Schliemann, Christoph, additional, Schetelig, Johannes, additional, Röllig, Christoph, additional, Kramer, Michael, additional, Glass, Bertram, additional, Platzbecker, Uwe, additional, Burchert, Andreas, additional, Hänel, Mathias, additional, Müller, Lutz P., additional, Klein, Stefan, additional, Bug, Gesine, additional, Beelen, Dietrich, additional, Rösler, Wolf, additional, Schäfer-Eckart, Kerstin, additional, Schmid, Christoph, additional, Jost, Edgar, additional, Lenz, Georg, additional, Tischer, Johanna, additional, Spiekermann, Karsten, additional, Pfirrmann, Markus, additional, Serve, Hubert, additional, Stölzel, Friedrich, additional, Alakel, Nael, additional, Middeke, Jan Moritz, additional, Thiede, Christian, additional, Ehninger, Gerhard, additional, Berdel, Wolfgang E., additional, and Stelljes, Matthias, additional

Published
2023
Full Text
View/download PDF

21. General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemia

Author

Gökbuget, Nicola, primary, Ihrig, Kristina, additional, Stadler, Michael, additional, Stelljes, Matthias, additional, Elmaagli, Ahmed, additional, Starck, Michael, additional, Raffel, Simon, additional, Stoltefuss, Andrea, additional, Viardot, Andreas, additional, Kreuzer, Karl-Anton, additional, Heidenreich, Daniela, additional, Renzelmann, Andrea, additional, Wäsch, Ralph, additional, Topp, Max S., additional, Ritter, Barbara, additional, Reimer, Peter, additional, Beck, Joachim, additional, Westermann, Jörg, additional, Wendelin, Knut, additional, Alakel, Nael, additional, Hanoun, Maher, additional, Serve, Hubert, additional, and Hoelzer, Dieter, additional

Published
2023
Full Text
View/download PDF

22. Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial

Author

Denkinger, Claudia M., primary, Janssen, Maike, additional, Schäkel, Ulrike, additional, Gall, Julia, additional, Leo, Albrecht, additional, Stelmach, Patrick, additional, Weber, Stefan F., additional, Krisam, Johannes, additional, Baumann, Lukas, additional, Stermann, Jacek, additional, Merle, Uta, additional, Weigand, Markus A., additional, Nusshag, Christian, additional, Bullinger, Lars, additional, Schrezenmeier, Jens-Florian, additional, Bornhäuser, Martin, additional, Alakel, Nael, additional, Witzke, Oliver, additional, Wolf, Timo, additional, Vehreschild, Maria J. G. T., additional, Schmiedel, Stefan, additional, Addo, Marylyn M., additional, Herth, Felix, additional, Kreuter, Michael, additional, Tepasse, Phil-Robin, additional, Hertenstein, Bernd, additional, Hänel, Mathias, additional, Morgner, Anke, additional, Kiehl, Michael, additional, Hopfer, Olaf, additional, Wattad, Mohammad-Amen, additional, Schimanski, Carl C., additional, Celik, Cihan, additional, Pohle, Thorsten, additional, Ruhe, Matthias, additional, Kern, Winfried V., additional, Schmitt, Anita, additional, Lorenz, Hanns-Martin, additional, Souto-Carneiro, Margarida, additional, Gaeddert, Mary, additional, Halama, Niels, additional, Meuer, Stefan, additional, Kräusslich, Hans-Georg, additional, Müller, Barbara, additional, Schnitzler, Paul, additional, Parthé, Sylvia, additional, Bartenschlager, Ralf, additional, Gronkowski, Martina, additional, Klemmer, Jennifer, additional, Schmitt, Michael, additional, Dreger, Peter, additional, Kriegsmann, Katharina, additional, Schlenk, Richard F., additional, and Müller-Tidow, Carsten, additional

Published
2022
Full Text
View/download PDF

23. 1142. Plasma with high titers of anti-SARS-Cov2 antibodies improves outcome of COVID-19 in patients with hematological malignancy and cancer in a randomized controlled trial

Author

Denkinger, Claudia M, primary, Janssen, Maike, additional, Schäkel, Ulrike, additional, Gall, Julia, additional, Leo, Albrecht, additional, Stelmach, Patrick, additional, Weber, Stefan F, additional, Krisam, Johannes, additional, Baumann, Lukas, additional, Stermann, Jacek, additional, Merle, Uta, additional, Weigand, Markus, additional, Bullinger, Lars, additional, Schrezenmeier, Jens-Florian, additional, Bornhäuser, Martin, additional, Alakel, Nael, additional, Witzke, Oliver, additional, Wolf, Timo, additional, Vehreschild, Maria, additional, Schmiedel, Stefan, additional, Addo, Marylyn, additional, Herth, Felix, additional, Kreuter, Michael, additional, Tepasse, Phil-Robin, additional, Hertenstein, Bernd, additional, Hänel, Mathias, additional, Morgner, Anke, additional, Kiehl, Michael, additional, Hopfer, Olaf, additional, Wattad, Mohammad-Amen, additional, Schimanski, Carl, additional, Celik, Cihan, additional, Pohle, Thorsten, additional, Ruhe, Matthias, additional, Kern, Winfried, additional, Schmitt, Anita, additional, Schmitt, Michael, additional, Lorenz, Hanns-Martin, additional, Souto-Carneiro, Margarida, additional, Halama, Niels, additional, Meurer, Stefan, additional, Kräusslich, Hans-Georg, additional, Müller, Barbara, additional, Bartenschlager, Ralf, additional, Gronkowski, Martina, additional, Klemmer, Jennifer, additional, Kriegsmann, Katharina, additional, Schlenk, Richard, additional, and Müller-Tidow, Carsten, additional

Published
2022
Full Text
View/download PDF

24. Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope

Author

Weinbergerová, Barbora, Sedlacek, Petr, Martino, Rodrigo, Kouba, Michal, Itzhak, Levy, Falces-Romero, Iker, Camus, Vincent, Arsenijevi'c, Valentina Arsi'c, Alakel, Nael, Pagano, Livio, Cornely, Oliver A., Busca, Alessandro, Buzzatti, Elisa, Delia, Mario, Califano, Catello, Paterno, Giovangiacinto, Cesaro, Simone, Basilico, Claudia Maria, Melillo, Lorella Maria Antonia, Stanzani, Marta, Demeter, Judit, Duarte, Rafael F., Demiraslan, Hayati, Yilmaz Karapinar, Deniz, Spolzino, Angelica, Klimko, Nikolai, Cattaneo, Chiara, Fracchiolla, Nicola, Koehler, Philipp, Nadali, Gianpaolo, Marchesi, Francesco, Piedimonte, Monica, Rácil, Zdenek, Dargenio, Michelina, Criscuolo, Marianna, Seidel, Danila, and Del Principe, Maria Ilaria

Subjects
Adult, Male, Saprochaete, Antifungal Agents, Adolescent, Hematological Malignancies, Diseases, Dermatology, Clavata, Guidelines, Young Adult, Echinocandins, Trichosporon, Humans, Child, Aged, Capitatus, fungal infection, Candidemia, General Medicine, Hematology, Middle Aged, Prognosis, Settore MED/15, Geotrichum, Management, Settore MED/15 - MALATTIE DEL SANGUE, antifungal treatment, Infectious Diseases, Child, Preschool, Magnusiomyces, Invasive Infections, Female, Fungal-Infection
Abstract

© 2022 Wiley-VCH GmbH.Background: Our multicentre study aims to identify baseline factors and provide guidance for therapeutic decisions regarding Magnusiomyces-associated infections, an emerging threat in patients with haematological malignancies. Methods: HM patients with proven (Magnusiomyces capitatus) M. capitatus or (Magnusiomyces clavatus) M. clavatus (formerly Saprochaete capitata and Saprochaete clavata) infection diagnosed between January 2010 and December 2020 were recorded from the SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group and FungiScope (Global Emerging Fungal Infection Registry). Cases of Magnusiomyces fungemia were compared with candidemia. Results: Among 90 Magnusiomyces cases (60 [66%] M. capitatus and 30 (34%) M. clavatus), median age was 50 years (range 2–78), 46 patients (51%) were female and 67 (74%) had acute leukaemia. Thirty-six (40%) of Magnusiomyces-associated infections occurred during antifungal prophylaxis, mainly with posaconazole (n = 13, 36%) and echinocandins (n = 12, 34%). Instead, the candidemia rarely occurred during prophylaxis (p

Published
2022

25. Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL

Author

Goekbuget, Nicola, primary, Fiedler, Walter, additional, Alakel, Nael, additional, Topp, Max S., additional, Hanoun, Maher, additional, Steffen, Björn, additional, Wäsch, Ralph, additional, Viardot, Andreas, additional, Nachtkamp, Kathrin, additional, Stelljes, Matthias, additional, Poeck, Hendrik, additional, Vucinic, Vladan, additional, Böll, Boris, additional, Beck, Joachim, additional, Fransecky, Lars, additional, Wendelin, Knut, additional, Schneller, Folker, additional, Faul, Christoph, additional, Buecklein, Veit L, additional, Reiser, Lena, additional, Brüggemann, Monika, additional, Serve, Hubert, additional, and Schwartz, Stefan, additional

Published
2022
Full Text
View/download PDF

26. Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial

Author

Röllig, Christoph, primary, Steffen, Björn, additional, Schliemann, Christoph, additional, Mikesch, Jan-Henrik, additional, Alakel, Nael, additional, Herbst, Regina, additional, Haenel, Mathias, additional, Noppeney, Richard, additional, Hanoun, Maher, additional, Kaufmann, Martin, additional, Racil, Zdenek, additional, Schäfer-Eckart, Kerstin, additional, Sauer, Tim, additional, Neubauer, Andreas, additional, Baldus, Claudia D., additional, Mertova, Jolana, additional, Jost, Edgar, additional, Niemann, Dirk, additional, Novak, Jan, additional, Krause, Stefan W., additional, Scholl, Sebastian, additional, Hochhaus, Andreas, additional, Held, Gerhard, additional, Szotkowski, Tomáš, additional, Schmid, Christoph, additional, Rank, Andreas, additional, Fransecky, Lars, additional, Kramer, Michael, additional, Fiebig, Frank, additional, Haake, Annett, additional, Stoelzel, Friedrich, additional, Schetelig, Johannes, additional, Middeke, Jan Moritz, additional, Platzbecker, Uwe, additional, Thiede, Christian, additional, Müller-Tidow, Carsten, additional, Berdel, Wolfgang E., additional, Serve, Hubert, additional, Ehninger, Gerhard, additional, Mayer, Jiří, additional, and Bornhaeuser, Martin, additional

Published
2022
Full Text
View/download PDF

27. Outcome of 841 Older Patients (&gt;55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols

Author

Goekbuget, Nicola, primary, Viardot, Andreas, additional, Steffen, Björn, additional, Hahn, Joachim, additional, Spriewald, Bernd, additional, Martin, Sonja, additional, Raffel, Simon, additional, Teichmann, Lino L., additional, Trummer, Arne, additional, Alsdorf, Winfried, additional, Morgner, Anke, additional, Schwartz, Stefan, additional, Stelljes, Matthias, additional, Vucinic, Vladan, additional, Alakel, Nael, additional, Stoltefuß, Andrea, additional, Baldus, Claudia D., additional, Brüggemann, Monika, additional, Serve, Hubert, additional, and Hoelzer, Dieter, additional

Published
2022
Full Text
View/download PDF

28. In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial

Author

Stelljes, Matthias, primary, Middeke, Jan Moritz, additional, Bug, Gesine, additional, Wagner, Eva-Maria, additional, Mueller, Lutz Peter, additional, Christoph, Schmid, additional, Krause, Stefan W., additional, Bethge, Wolfgang, additional, Jost, Edgar, additional, Platzbecker, Uwe, additional, Klein, Stefan, additional, Schubert, Jörg, additional, Niederland, Judith, additional, Kaufmann, Martin, additional, Schäfer-Eckart, Kerstin, additional, Schaich, Markus, additional, Baldauf, Henning, additional, Stölzel, Friedrich, additional, Petzold, Cathleen, additional, Röllig, Christoph, additional, Alakel, Nael, additional, Steffen, Björn, additional, Hauptrock, Beate, additional, Reicherts, Christian, additional, Schliemann, Christoph, additional, Serve, Hubert, additional, Schmidt, Alexander H., additional, Bornhäuser, Martin, additional, Mikesch, Jan-Henrik, additional, and Schetelig, Johannes, additional

Published
2022
Full Text
View/download PDF

29. Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (&gt;55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)

Author

Stelljes, Matthias, primary, Alakel, Nael, additional, Wäsch, Ralph, additional, Scholl, Sebastian, additional, Nachtkamp, Kathrin, additional, Rank, Andreas, additional, Haenel, Mathias, additional, Spriewald, Bernd, additional, Hanoun, Maher, additional, Martin, Sonja, additional, Schwab, Katjana, additional, Knaden, Julian, additional, Reiser, Lena, additional, Marx, Julia, additional, Wethmar, Klaus, additional, Sauer, Tim, additional, Berdel, Wolfgang E., additional, Lenz, Georg, additional, Brüggemann, Monika, additional, Raffel, Simon, additional, and Goekbuget, Nicola, additional

Published
2022
Full Text
View/download PDF

30. Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial

Author

Röllig, Christoph, primary, Fransecky, Lars, additional, Hanoun, Maher, additional, Steffen, Björn, additional, Kraus, Sabrina, additional, Schliemann, Christoph, additional, Haake, Annett, additional, Fiebig, Frank, additional, Zukunft, Sven, additional, Alakel, Nael, additional, Middeke, Jan Moritz, additional, Bornhaeuser, Martin, additional, Stoelzel, Friedrich, additional, Schetelig, Johannes, additional, Ruhnke, Leo, additional, Kramer, Michael, additional, Von Bonin, Malte, additional, Röhnert, Maximilian Alexander, additional, Oelschlägel, Uta, additional, Baldus, Claudia D., additional, Serve, Hubert, additional, and Wermke, Martin, additional

Published
2022
Full Text
View/download PDF

31. Outcome of 841 Older Patients (>55 yrs) with Newly Diagnosed Ph/BCR-ABL Negative ALL Prospectively Treated According to Pediatric-Based, Age-Adapted GMALL Protocols

Author

Goekbuget, Nicola, Viardot, Andreas, Steffen, Björn, Hahn, Joachim, Spriewald, Bernd, Martin, Sonja, Raffel, Simon, Teichmann, Lino L., Trummer, Arne, Alsdorf, Winfried, Morgner, Anke, Schwartz, Stefan, Stelljes, Matthias, Vucinic, Vladan, Alakel, Nael, Stoltefuß, Andrea, Baldus, Claudia D., Brüggemann, Monika, Serve, Hubert, and Hoelzer, Dieter

Published
2022
Full Text
View/download PDF

32. Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with intermediate-risk - results of the randomized ETAL-1 trial

Author

Bornhauser, Martin, primary, Schliemann, Christoph, additional, Schetelig, Johannes, additional, Röllig, Christoph, additional, Kramer, Michael, additional, Glass, Bertram, additional, Platzbecker, Uwe, additional, Burchert, Andreas, additional, Hänel, Mathias, additional, Muller, Lutz, additional, Klein, Stefan, additional, Bug, Gesine, additional, Beelen, Dietrich, additional, Rösler, Wolf, additional, Schäfer-Eckart, Kerstin, additional, Schmid, Christoph, additional, Jost, Edgar, additional, Lenz, Georg, additional, Tischer, Johanna, additional, Spiekermann, Karsten, additional, Pfirrmann, Markus, additional, Serve, Hubert, additional, Stölzel, Friedrich, additional, Alakel, Nael, additional, Middeke, Jan Moritz, additional, Thiede, Christian, additional, Ehninger, Gerhard, additional, Berdel, Wolfgang, additional, and Stelljes, Matthias, additional

Published
2022
Full Text
View/download PDF

33. Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL/T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL

Author

Goekbuget, Nicola, Fiedler, Walter, Alakel, Nael, Topp, Max S., Hanoun, Maher, Steffen, Bjoern, Waesch, Ralph, Viardot, Andreas, Nachtkamp, Kathrin, Stelljes, Matthias, Poeck, Hendrik, Vucinic, Vladan, Boell, Boris, Beck, Joachim, Fransecky, Lars, Wendelin, Knut, Schneller, Folker, Faul, Christoph, Buecklein, Veit L., Reiser, Lena, Brueggemann, Monika, Serve, Hubert, Schwartz, Stefan, Goekbuget, Nicola, Fiedler, Walter, Alakel, Nael, Topp, Max S., Hanoun, Maher, Steffen, Bjoern, Waesch, Ralph, Viardot, Andreas, Nachtkamp, Kathrin, Stelljes, Matthias, Poeck, Hendrik, Vucinic, Vladan, Boell, Boris, Beck, Joachim, Fransecky, Lars, Wendelin, Knut, Schneller, Folker, Faul, Christoph, Buecklein, Veit L., Reiser, Lena, Brueggemann, Monika, Serve, Hubert, and Schwartz, Stefan

Published
2022

35. Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial-

Author

Bornhaeuser, Martin, primary, Schliemann, Christoph, additional, Schetelig, Johannes, additional, Rollig, Christoph, additional, Kramer, Michael, additional, Glass, Bertram, additional, Platzbecker, Uwe, additional, Burchert, Andreas, additional, Haenel, Mathias, additional, Mueller, Lutz Peter, additional, Klein, Stefan, additional, Bug, Gesine, additional, Beelen, Dietrich W., additional, Roesler, Wolf, additional, Schaefer-Eckart, Kerstin, additional, Schmid, Christoph, additional, Jost, Edgar, additional, Lenz, Georg, additional, Tischer, Johanna, additional, Spiekermann, Karsten, additional, Pfirrmann, Markus, additional, Serve, Hubert, additional, Stoelzel, Friedrich, additional, Alakel, Nael, additional, Ehninger, Gerhard, additional, Berdel, Wolfgang E., additional, and Stelljes, Matthias, additional

Published
2021
Full Text
View/download PDF

36. First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL)

Author

Goekbuget, Nicola, primary, Stelljes, Matthias, additional, Viardot, Andreas, additional, Nachtkamp, Kathrin, additional, Steffen, Björn, additional, Schneller, Folker, additional, Alakel, Nael, additional, Topp, Max, additional, Böll, Boris, additional, Faul, Christoph, additional, Spiekermann, Karsten, additional, Wendelin, Knut, additional, Hanoun, Maher, additional, Wäsch, Ralph, additional, Beck, Joachim, additional, Martin, Sonja, additional, Vucinic, Vladan, additional, Baldus, Claudia D., additional, Brüggemann, Monika, additional, Burmeister, Thomas, additional, Pfeifer, Heike, additional, Schwartz, Stefan, additional, Baumann, Lena, additional, Tichy, Diana, additional, Serve, Hubert, additional, and Fiedler, Walter, additional

Published
2021
Full Text
View/download PDF

37. Gemtuzumab Ozogamicin Plus Midostaurin in Combination with Standard Intensive Induction Therapy in Newly Diagnosed AML: Results from a Phase-I Study

Author

Röllig, Christoph, primary, Schliemann, Christoph, additional, Mikesch, Jan-Henrik, additional, Fransecky, Lars, additional, Baldus, Claudia D., additional, Heydrich, Björn-Niklas, additional, Hanoun, Maher, additional, Noppeney, Richard, additional, Scholl, Sebastian, additional, Schnetzke, Ulf, additional, Schäfer-Eckart, Kerstin, additional, Wendelin, Knut, additional, Wermke, Martin, additional, Reimann, Manja, additional, Fiebig, Frank, additional, Kretschmann, Theresa, additional, Stoelzel, Friedrich, additional, Alakel, Nael, additional, and Bornhäuser, Martin, additional

Published
2021
Full Text
View/download PDF

38. Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial)

Author

Stelljes, Matthias, primary, Alakel, Nael, additional, Wäsch, Ralph, additional, Scholl, Sebastian, additional, Nachtkamp, Kathrin, additional, Rank, Andreas, additional, Haenel, Mathias, additional, Spriewald, Bernd, additional, Hanoun, Maher, additional, Martin, Sonja, additional, Schwab, Katjana, additional, Knaden, Julian, additional, Marx, Julia, additional, Wethmar, Klaus, additional, Sauer, Tim, additional, Berdel, Wolfgang E., additional, Lenz, Georg, additional, Dugas, Martin, additional, Goekbuget, Nicola, additional, Brueggemann, Monika, additional, and Raffel, Simon, additional

Published
2021
Full Text
View/download PDF

39. Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia

Author

Rautenberg, Christina, primary, Stölzel, Friedrich, additional, Röllig, Christoph, additional, Stelljes, Matthias, additional, Gaidzik, Verena I, additional, Lauseker, Michael, additional, Kriege, Oliver, additional, Verbeek, Mareike, additional, Unglaub, Julia M., additional, Thol, Felicitas, additional, Krause, Stefan W., additional, Haenel, Mathias, additional, Neuerburg, Charlotte, additional, Vucinic, Vladan, additional, Jehn, Christian, additional, Severmann, Julia, additional, Wass, Maxi, additional, Fransecky, Lars, additional, Chemnitz, Jens, additional, Holtick, Udo, additional, Schäfer-Eckart, Kerstin, additional, Schröder, Josephine, additional, Kraus, Sabrina, additional, Krüger, William Hermann, additional, Kaiser, Ulrich, additional, Scholl, Sebastian, additional, Henning, Lea, additional, Kobbe, Guido, additional, Haas, Rainer, additional, Alakel, Nael, additional, Röhnert, Maximilian Alexander, additional, Sockel, Katja, additional, Hanoun, Maher, additional, Platzbecker, Uwe, additional, Holderried, Tobias A. W., additional, Morgner, Anke, additional, Heuser, Michael, additional, Sauer, Tim, additional, Goetze, Katharina S., additional, Wagner, Eva Maria, additional, Döhner, Konstanze, additional, Döhner, Hartmut, additional, Schliemann, Christoph, additional, Schetelig, Johannes, additional, Bornhäuser, Martin, additional, Germing, Ulrich, additional, Schroeder, Thomas, additional, and Middeke, Moritz Moritz, additional

Published
2021
Full Text
View/download PDF

40. Half-dose glucarpidase as efficient rescue for toxic methotrexate levels in patients with acute kidney injury

Author

Heuschkel, Sandra, primary, Kretschmann, Theresa, additional, Teipel, Raphael, additional, von Bonin, Simone, additional, Richter, Stephan, additional, Quick, Susanne, additional, Alakel, Nael, additional, Röllig, Christoph, additional, Balaian, Ekaterina, additional, Kroschinsky, Frank, additional, Knoth, Holger, additional, Bornhäuser, Martin, additional, and von Bonin, Malte, additional

Published
2021
Full Text
View/download PDF

42. Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial

Author

Röllig, Christoph, Steffen, Björn, Alakel, Nael, Herbst, Regina, Noppeney, Richard, Hanoun, Maher, Racil, Zdenek, Schäfer-Eckart, Kerstin, Krämer, Alwin, Neubauer, Andreas, Baldus, Claudia D, Schliemann, Christoph, Kaufmann, Martin, Mertova, Jolana, Jost, Edgar, Niemann, Dirk, Novak, Jan, Krause, Stefan W, Scholl, Sebastian, Held, Gerhard, Parmentier, Stefani B., Szotkowski, Tomáš, Zak, Pavel, Rank, Andreas, Wass, Maxi, Buske, Sebastian, Kramer, Michael, Fiebig, Frank, Haake, Annett, Schetelig, Johannes, Platzbecker, Uwe, Thiede, Christian, Müller-Tidow, Carsten, Berdel, Wolfgang E., Serve, Hubert, Ehninger, Gerhard, Mayer, Jiri, and Bornhäuser, Martin

Published
2020
Full Text
View/download PDF

43. Leitlinie : Empfehlungen der Fachgesellschaft zur Diagnostik und Therapie h��matologischer und onkologischer Erkrankungen

Author

Cla��en, Annika, Penack, Olaf, Lilienfeld-Toal, Marie Von, Maschmeyer, Georg, Krause, Stefan, Neumann, Silke, Sandherr, Michael, Wolf, Hans-Heinrich, Vehreschild, J��rg Janne, Alakel, Nael, Cornely, Oliver Andreas, Dur��n Graeff, Luisa A., Christopeit, Maximilian Erich Joachim, Wei��inger, Florian, Henze, Larissa, Deutsche Gesellschaft F��r H��matologie Und Medizinische Onkologie, and Mayer, Karin Tina

Subjects
Medizin und Gesundheit
Published
2021
Full Text
View/download PDF

44. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia

Author

Rautenberg, Christina, Stölzel, Friedrich, Röllig, Christoph, Stelljes, Matthias, Gaidzik, Verena, Lauseker, Michael, Kriege, Oliver, Verbeek, Mareike, Unglaub, Julia Marie, Thol, Felicitas, Krause, Stefan W., Hänel, Mathias, Neuerburg, Charlotte, Vucinic, Vladan, Jehn, Christian-Friedrich, Severmann, Julia, Wass, Maxi, Fransecky, Lars, Chemnitz, Jens, Holtick, Udo, Schäfer-Eckart, Kerstin, Schröder, Josephine, Kraus, Sabrina, Krüger, William, Kaiser, Ulrich, Scholl, Sebastian, Koch, Kathrin, Henning, Lea, Kobbe, Guido, Haas, Rainer, Alakel, Nael, Röhnert, Maximilian-Alexander, Sockel, Katja, Hanoun, Maher, Platzbecker, Uwe, Holderried, Tobias A. W., Morgner, Anke, Heuser, Michael, Sauer, Tim, Götze, Katharina S., Wagner-Drouet, Eva, Döhner, Konstanze, Döhner, Hartmut, Schliemann, Christoph, Schetelig, Johannes, Bornhäuser, Martin, Germing, Ulrich, Schroeder, Thomas, and Middeke, Jan Moritz

Subjects
Article, Haematological cancer, Leukaemia, ddc
Published
2020

46. Efficacy of UVC-treated, pathogen-reduced platelets versus untreated platelets: a randomized controlled non-inferiority trial

Author

Brixner, Veronika, primary, Bug, Gesine, additional, Pohler, Petra, additional, Krämer, Doris, additional, Metzner, Bernd, additional, Voß, Andreas, additional, Casper, Jochen, additional, Ritter, Ulrich, additional, Klein, Stefan, additional, Alakel, Nael, additional, Peceny, Rudolf, additional, Derigs, Hans G., additional, Stegelmann, Frank, additional, Wolf, Martin, additional, Schrezenmeier, Hubert, additional, Thiele, Thomas, additional, Seifried, Erhard, additional, Kapels, Hans-Hermann, additional, Döscher, Andrea, additional, Petershofen, Eduard K., additional, Müller, Thomas H., additional, and Seltsam, Axel, additional

Published
2021
Full Text
View/download PDF

47. Molecular Subgroups of T Cell Acute Lymphoblastic Leukemia in Adults Treated According to GMALL Protocols

Author

Neumann, Martin, primary, Bastian, Lorenz, additional, Hänzelmann, Sonja, additional, Hartmann, Alina, additional, Trautmann, Heiko, additional, Tanchez, Jutta Ortiz, additional, Schlee, Cornelia, additional, Schroeder, Michael P, additional, Fransecky, Lars R., additional, Vosberg, Sebastian, additional, Fiedler, Walter, additional, Alakel, Nael, additional, Kondakci, Mustafa, additional, Starck, Michael, additional, Schwartz, Stefan, additional, Müller-Tidow, Carsten, additional, Schneller, Folker, additional, Reichle, Albert, additional, Burmeister, Thomas, additional, Greif, Philipp A., additional, Brüggemann, Monika, additional, Goekbuget, Nicola, additional, and Baldus, Claudia D, additional

Published
2020
Full Text
View/download PDF

48. First Results of an Open Label Phase II Study to Evaluate the Efficacy and Safety of Inotuzumab Ozogamicin for Induction Therapy Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute Lymphoblastic Leukemia (INITIAL-1 trial)

Author

Stelljes, Matthias, primary, Raffel, Simon, additional, Wäsch, Ralph, additional, Scholl, Sebastian, additional, Kondakci, Mustafa, additional, Rank, Andreas, additional, Haenel, Mathias, additional, Martin, Sonja, additional, Schwab, Katjana, additional, Knaden, Julian, additional, Wethmar, Klaus, additional, Sauer, Tim, additional, Berdel, Wolfgang E., additional, Lenz, Georg, additional, Dugas, Martin, additional, Brüggemann, Monika, additional, Goekbuget, Nicola, additional, and Alakel, Nael, additional

Published
2020
Full Text
View/download PDF

49. Interim Results of a Multicenter, Single-Arm Study to Assess Blinatumomab in Adult Patients (pts) with Minimal Residual Disease (MRD) of B-Precursor (BCP) Acute Lymphoblastic Leukemia (GMALL-MOLACT1-BLINA)

Author

Goekbuget, Nicola, primary, Wermann, Wiba Keke, additional, Schwartz, Stefan, additional, Hüttmann, Andreas, additional, Faul, Christoph, additional, Raffel, Simon, additional, Viardot, Andreas, additional, Fiedler, Walter, additional, Alakel, Nael, additional, Stelljes, Matthias, additional, Subklewe, Marion, additional, Wäsch, Ralph, additional, Martin, Sonja, additional, Jung, Wolfram, additional, Vucinic, Vladan, additional, Kondakci, Mustafa, additional, Fransecky, Lars R., additional, Heidenreich, Daniela, additional, Wendelin, Knut, additional, Hermann, Julian, additional, Serve, Hubert, additional, Bargou, Ralf C, additional, Topp, Max S., additional, and Brüggemann, Monika, additional

Published
2020
Full Text
View/download PDF

50. 1598. Clinical implications of azole-resistant vs. azole-susceptible invasive aspergillosis in hematological malignancy (CLARITY) – a multicenter study

Author

Seidel, Danila, primary, Cornely, Oliver, additional, Zarrouk, Marouan, additional, Koehler, Philipp, additional, Meis, Jacques F, additional, Salmanton-García, Jon, additional, Vehreschild, Jörg Janne, additional, Christner, Martin, additional, Gräfe, Stefanie K, additional, Falces-Romero, Iker, additional, Lagrou, Katrien, additional, Maertens, Johan, additional, Reséndiz- Sharpe, Agustín, additional, Racil, Zdenek, additional, Weinbergerová, Barbora, additional, Valerio, Maricela, additional, Muñoz, Patricia, additional, Blennow, Ola, additional, Rammaert, Blandine, additional, Ostojic, Alen, additional, Govic, Yohann Le, additional, Lass-Flörl, Cornelia, additional, Rössler, Susann, additional, van Dijk, Karin, additional, de Jong, Nick, additional, Steinmann, Jörg, additional, Desoubeaux, Guillaume, additional, Alakel, Nael, additional, Klimko, Nikolay, additional, Schalk, Enrico, additional, Brenier-Pinchart, Marie-Pierre, additional, Garcia-Vidal, Carolina, additional, Bergeron, Anne, additional, Cho, Sung-Yeon, additional, Melchers, Willem J G, additional, Vehreschild, Maria J G T, additional, and Verweij, Paul E, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results